Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totalling 19,000 shares, a drop of 92.1% from the December 31st total of 241,700 shares. Currently, 1.3% of the company’s shares are sold short. Based on an average trading volume of 325,400 shares, the short-interest ratio is currently 0.1 days.
Aptevo Therapeutics Trading Up 0.9 %
Aptevo Therapeutics stock opened at $4.53 on Wednesday. Aptevo Therapeutics has a 12-month low of $3.65 and a 12-month high of $399.60. The firm’s fifty day moving average is $85.17 and its 200 day moving average is $297.46.
Analyst Upgrades and Downgrades
Separately, StockNews.com assumed coverage on Aptevo Therapeutics in a research report on Monday, December 9th. They set a “sell” rating on the stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
See Also
- Five stocks we like better than Aptevo Therapeutics
- Stock Sentiment Analysis: How it Works
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How Can Investors Benefit From After-Hours Trading
- What Does the Future Hold for Eli Lilly?
- About the Markup Calculator
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
